Cipla
-
{
- All
- News
- Videos
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
- Monday January 26, 2026
- Health | Indo-Asian News Service
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
www.ndtv.com/health
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
- Sunday May 5, 2024
- India News | Press Trust of India
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
www.ndtv.com
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
- Friday July 7, 2023
- India News | Press Trust of India
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
www.ndtv.com
-
Moderna Approved For Emergency Use, 4th Vaccine Okayed By India
- Tuesday June 29, 2021
- India News | Reported by Sukirti Dwivedi
The government on Tuesday cleared the fourth vaccine for emergency use in the country, the US-made Moderna.
-
www.ndtv.com
-
Cipla Close To Committing Over $1 Billion For Moderna Booster Vaccine In India: Report
- Tuesday June 1, 2021
- India News | Press Trust of India
Seeking fast-track approvals to bring Moderna's single-dose COVID-19 booster vaccine in India expeditiously, Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty.
-
www.ndtv.com
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
- Monday May 10, 2021
- India News | Reuters
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
www.ndtv.com
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
- Tuesday August 11, 2020
- World News | Reuters
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
www.ndtv.com
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
- Friday July 24, 2020
- India News | Press Trust of India
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
-
www.ndtv.com
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Sources
- Wednesday July 8, 2020
- World News | Reuters
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
-
www.ndtv.com
-
Cipla Q2 Profit Soars 19 per Cent To Rs 423 Crore On Higher Domestic Sales
- Tuesday November 7, 2017
- Business | Thomson Reuters
Cipla posted its second straight rise in quarterly profit, slightly above analysts' estimate, boosted by strong domestic sales.
-
www.ndtv.com/business
-
Rs 1 Crore a Day. One Donor's Offer for Earthquake-hit Nepal at Delhi Embassy
- Tuesday April 28, 2015
- India News | Written by Sunetra Choudhury
If you are in despair about the tragedy in Nepal, come down to the Nepalese Embassy in Delhi. The kindness of the many, many people who have reached out in this time of need, is bound to warm your heart.
-
www.ndtv.com
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
- Monday January 26, 2026
- Health | Indo-Asian News Service
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
www.ndtv.com/health
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
- Sunday May 5, 2024
- India News | Press Trust of India
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
www.ndtv.com
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
- Friday July 7, 2023
- India News | Press Trust of India
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
www.ndtv.com
-
Moderna Approved For Emergency Use, 4th Vaccine Okayed By India
- Tuesday June 29, 2021
- India News | Reported by Sukirti Dwivedi
The government on Tuesday cleared the fourth vaccine for emergency use in the country, the US-made Moderna.
-
www.ndtv.com
-
Cipla Close To Committing Over $1 Billion For Moderna Booster Vaccine In India: Report
- Tuesday June 1, 2021
- India News | Press Trust of India
Seeking fast-track approvals to bring Moderna's single-dose COVID-19 booster vaccine in India expeditiously, Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty.
-
www.ndtv.com
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
- Monday May 10, 2021
- India News | Reuters
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
www.ndtv.com
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
- Tuesday August 11, 2020
- World News | Reuters
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
www.ndtv.com
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
- Friday July 24, 2020
- India News | Press Trust of India
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
-
www.ndtv.com
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Sources
- Wednesday July 8, 2020
- World News | Reuters
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
-
www.ndtv.com
-
Cipla Q2 Profit Soars 19 per Cent To Rs 423 Crore On Higher Domestic Sales
- Tuesday November 7, 2017
- Business | Thomson Reuters
Cipla posted its second straight rise in quarterly profit, slightly above analysts' estimate, boosted by strong domestic sales.
-
www.ndtv.com/business
-
Rs 1 Crore a Day. One Donor's Offer for Earthquake-hit Nepal at Delhi Embassy
- Tuesday April 28, 2015
- India News | Written by Sunetra Choudhury
If you are in despair about the tragedy in Nepal, come down to the Nepalese Embassy in Delhi. The kindness of the many, many people who have reached out in this time of need, is bound to warm your heart.
-
www.ndtv.com